Uni-Bio Science Group Limited (0690.HK)

HKD 0.07

(-4.05%)

Market Cap (In HKD)

417.85 Million

Revenue (In HKD)

484.71 Million

Net Income (In HKD)

70.87 Million

Avg. Volume

8.04 Million

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.046-0.109
PE
3.55
EPS
0.02
Beta Value
-0.144
ISIN
KYG9198H1406
CUSIP
-
CIK
-
Shares
5885230000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Zhi Gang Zhao CPA, MSc
Employee Count
-
Website
https://www.uni-bioscience.com
Ipo Date
2001-11-12
Details
Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF eye drop for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agonist, a non-insulin treatment candidate for the treatment of Type 2 diabetes. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong.